Mylan boosted as Teva's generic EpiPen delayed

Robert Coury

Allergy treatment EpiPen generated over $1 billion sales revenue for Mylan in 2015.

A laconic report by Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) to the Securities and Exchange Commission in the US represents good news for its competitor Mylan: a further delay in the launch of Teva's generic version of Mylan's most important ethical drug, EpiPen (epinephrine).

Teva's notice states: "Teva received a complete response letter on February 23, 2016 relating to its epinephrine ANDA in which the FDA identified certain major deficiencies. Teva is evaluating the CRL and intends to submit a response. Due to the major nature of the CRL, Teva expects that its epinephrine product will be significantly delayed and that any launch will not take place before 2017."

EpiPen came to Mylan through the acquisition of the generics arm of German company Merck KGaA in 2007. The drug is an injection for treating severe allergies. In 2014, sales of EpiPen surpassed the $1 billion mark for the first time, and 2015 sales were also above that level. Mylan's total sales in 2015 were $9.4 billion. Mylan recently raised the price of EpiPen by 14.9%, which contributed to the rise in its sales revenue last year. Mylan also benefitted from the fact that Sanofi's rival drug Auvi-Q was recently removed from the shelves by Sanofi itself because of quality problems.

Teva had previously announced an expected delay in launching its generic version of EpiPen, but estimated that its product would reach the market by mid-2016. Mylan, on the other hand, estimated that Teva might not be able to enter the market in 2016 at all.

Teva commented, "Teva received a complete response letter on February 23, 2016 relating to its epinephrine ANDA in which the FDA identified certain major deficiencies. Teva is evaluating the CRL and intends to submit a response. Due to the major nature of the CRL, Teva expects that its epinephrine product will be significantly delayed and that any launch will not take place before 2017. With regards to guidance, there is no impact on both the short- and long-term."

Published by Globes [online], Israel business news - www.globes-online.com - on March 1, 2016

© Copyright of Globes Publisher Itonut (1983) Ltd. 2016

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Robert Coury
Robert Coury
Twitter Facebook Linkedin RSS Newsletters גלובס Capital Markets Conference 2016